183 related articles for article (PubMed ID: 27784243)
1. Brain Drug Delivery Systems for the Stroke Intervention and Recovery.
Luo T; Wang J; Hao S; Guo T; Ren P; Cheng Z; Gao F; Gong Y; Wang B
Curr Pharm Des; 2017; 23(15):2258-2267. PubMed ID: 27784243
[TBL] [Abstract][Full Text] [Related]
2. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
[TBL] [Abstract][Full Text] [Related]
3. Liposomes for drug delivery in stroke.
Bruch GE; Fernandes LF; Bassi BLT; Alves MTR; Pereira IO; Frézard F; Massensini AR
Brain Res Bull; 2019 Oct; 152():246-256. PubMed ID: 31323280
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Fukuta T; Asai T; Yanagida Y; Namba M; Koide H; Shimizu K; Oku N
FASEB J; 2017 May; 31(5):1879-1890. PubMed ID: 28082354
[TBL] [Abstract][Full Text] [Related]
5. The application of nanoparticles for neuroprotection in acute ischemic stroke.
Chen L; Gao X
Ther Deliv; 2017 Oct; 8(10):915-928. PubMed ID: 28944741
[TBL] [Abstract][Full Text] [Related]
6. Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.
Fukuta T; Ishii T; Asai T; Oku N
Biol Pharm Bull; 2019; 42(3):319-326. PubMed ID: 30828062
[TBL] [Abstract][Full Text] [Related]
7. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice.
Chen TY; Lee MY; Chen HY; Kuo YL; Lin SC; Wu TS; Lee EJ
J Pineal Res; 2006 Apr; 40(3):242-50. PubMed ID: 16499561
[TBL] [Abstract][Full Text] [Related]
8. Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion injury following acute ischemic stroke in rats.
Turner RJ; Vink R
Neuroscience; 2012 Sep; 220():1-10. PubMed ID: 22750240
[TBL] [Abstract][Full Text] [Related]
9. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.
Vergouwen MD; Casaubon LK; Swartz RH; Fang J; Stamplecoski M; Kapral MK; Silver FL;
Stroke; 2011 Apr; 42(4):1041-5. PubMed ID: 21350204
[TBL] [Abstract][Full Text] [Related]
10. Stroke and Drug Delivery--In Vitro Models of the Ischemic Blood-Brain Barrier.
Tornabene E; Brodin B
J Pharm Sci; 2016 Feb; 105(2):398-405. PubMed ID: 26869407
[TBL] [Abstract][Full Text] [Related]
11. Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.
Wang W; Li M; Chen Q; Wang J
Mol Neurobiol; 2015 Dec; 52(3):1572-1579. PubMed ID: 25367883
[TBL] [Abstract][Full Text] [Related]
12. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
[TBL] [Abstract][Full Text] [Related]
13. Advanced drug delivery system against ischemic stroke.
Zhang S; Zhou Y; Li R; Chen Z; Fan X
J Control Release; 2022 Apr; 344():173-201. PubMed ID: 35248645
[TBL] [Abstract][Full Text] [Related]
14. Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke.
Shuayto MI; Lopez JI; Greiner F
J Child Neurol; 2006 Jul; 21(7):604-6. PubMed ID: 16970853
[TBL] [Abstract][Full Text] [Related]
15. Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles.
Han L; Cai Q; Tian D; Kong DK; Gou X; Chen Z; Strittmatter SM; Wang Z; Sheth KN; Zhou J
Nanomedicine; 2016 Oct; 12(7):1833-1842. PubMed ID: 27039220
[TBL] [Abstract][Full Text] [Related]
16. Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
Teng F; Beray-Berthat V; Coqueran B; Lesbats C; Kuntz M; Palmier B; Garraud M; Bedfert C; Slane N; Bérézowski V; Szeremeta F; Hachani J; Scherman D; Plotkine M; Doan BT; Marchand-Leroux C; Margaill I
Exp Neurol; 2013 Oct; 248():416-28. PubMed ID: 23876515
[TBL] [Abstract][Full Text] [Related]
17. Multimodal nanoprobes evaluating physiological pore size of brain vasculatures in ischemic stroke models.
Zheng S; Bai YY; Changyi Y; Gao X; Zhang W; Wang Y; Zhou L; Ju S; Li C
Adv Healthc Mater; 2014 Nov; 3(11):1909-18. PubMed ID: 24898608
[TBL] [Abstract][Full Text] [Related]
18. Reperfusion-Related Intracerebral Hemorrhage.
Hayakawa M
Front Neurol Neurosci; 2015; 37():62-77. PubMed ID: 26587772
[TBL] [Abstract][Full Text] [Related]
19. Will symptomatic intracerebral hemorrhages decrease among eligible dabigatran-treated patients who receive intravenous tissue plasminogen activator for acute ischemic stroke?
Chan L
Arch Neurol; 2010 Sep; 67(9):1156; author reply 1156-7. PubMed ID: 20837869
[No Abstract] [Full Text] [Related]
20. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
